Caffeine for apnea of prematurity: a neonatal success story.
K Kreutzer, D Bassler
https://pubmed.ncbi.nlm.nih.gov/24931325/Actively Recruiting
Led by Semmelweis University · Updated on 2024-05-06
226
Participants Needed
2
Research Sites
52 weeks
Total Duration
Researchers are studying whether giving a single additional loading dose of caffeine citrate one hour before extubation improves the success rate of extubation in preterm infants born before the 32nd week of gestation. The study also aims to evaluate how this intervention affects the frequency of apnea episodes, side effects, and the development of complications such as necrotizing enterocolitis, bronchopulmonary dysplasia, intraventricular hemorrhage, periventricular leukomalacia, and long-term neurodevelopmental outcomes. Participants include preterm neonates who have been mechanically ventilated for at least 48 hours before a planned extubation. They will be randomly assigned to one of two groups one will receive an additional intravenous loading dose of 20 mgkg caffeine citrate 60 minutes before extubation, while the other group will continue with the standard caffeine dosing regimen, which includes a loading dose on the first day of life and a maintenance dose of 5-10 mgkg daily. The trial will be conducted in neonatal intensive care units and includes careful stratification by gestational age and antenatal steroid use. During the study, researchers will monitor the need for reintubation within 48 hours after extubation as the primary outcome. They will also track secondary outcomes such as apnea frequency, heart rate changes, tachycardia, gastric residual volume, feeding reduction, blood pressure changes, days on mechanical or non-invasive ventilation, and rates of common complications in prematurity up to discharge or specific timepoints. Long-term neurodevelopmental outcomes will be assessed at two years of corrected age. Safety and side effects will be carefully observed throughout the study period.
CONDITIONS
The Effect of an Additional Pre-extubational Loading Dose of Caffeine-citrate
K
Kinga Kovács, MD.
Á
Ákos Gasparics, MD.PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Semmelweis University
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Until extubation and shortly after
Participants receive a loading dose of caffeine citrate on the first day of life and daily maintenance doses. Some participants will receive an additional loading dose of caffeine citrate 60 minutes before planned extubation.
1 to 2 visits including the pre-extubation dosing and extubation
Duration - 48 hours to 1 month after extubation
Participants are monitored for the need for reintubation, side effects, and adverse outcomes related to prematurity.
Daily assessments up to 48 hours and additional monitoring until discharge, approximately 1 month
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
K Kreutzer, D Bassler
https://pubmed.ncbi.nlm.nih.gov/24931325/Laura Moschino, Sanja Zivanovic, Caroline Hartley...
https://pubmed.ncbi.nlm.nih.gov/32154294/Barbara Schmidt, Robin S Roberts, Peter Davis...
https://pubmed.ncbi.nlm.nih.gov/17989382/Jing Chen, Lu Jin, Xiao Chen
https://pubmed.ncbi.nlm.nih.gov/30671477/Christopher McPherson, Jeffrey J Neil, Tiong Han Tjoeng...
https://pubmed.ncbi.nlm.nih.gov/25856169/Laura Chavez, Eduardo Bancalari
https://pubmed.ncbi.nlm.nih.gov/35691280/Jia-Yi Long, Hong-Li Guo, Xin He...
https://pubmed.ncbi.nlm.nih.gov/34381359/Kinga Kovács, Rita Nagy, Lilla Andréka...
https://pubmed.ncbi.nlm.nih.gov/39804861/Sameh Mohammed, Islam Nour, Abd Elazeez Shabaan...
https://pubmed.ncbi.nlm.nih.gov/25644724/Barbara Schmidt, Robin S Roberts, Peter Davis...
https://pubmed.ncbi.nlm.nih.gov/16707748/Semmelweis University
Lead Sponsor